Mostrar o rexistro simple do ítem

dc.contributor.authorGarcía González, Jorge José 
dc.contributor.authorRUIZ BAÑOBRE, JUAN 
dc.contributor.authorAfonso Afonso, Francisco Javier 
dc.contributor.authorAmenedo-Gancedo, Margarita
dc.contributor.authorAreses Manrique, María Carmen 
dc.contributor.authorCampos Balea, Begoña 
dc.contributor.authorCasal Rubio, Joaquín 
dc.contributor.authorFernández Nuñez, Natalia 
dc.contributor.authorFirvida Perez, Jose Luis 
dc.contributor.authorLazaro Quintela, Martín 
dc.contributor.authorPérez Parente, Diego 
dc.contributor.authorCrama, Leonardo
dc.contributor.authorRuiz-Gracia, Pedro
dc.contributor.authorSantomé-Couto, Lucía
dc.contributor.authorLeón Mateos, Luis Ángel 
dc.date.accessioned2022-03-17T08:20:39Z
dc.date.available2022-03-17T08:20:39Z
dc.date.issued2020
dc.identifier.issn2077-0383
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32635291es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16315
dc.description.abstractThe combination of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors with chemotherapy has emerged as a promising therapeutic option for advanced non-small-cell lung cancer (NSCLC). The aim of this meta-analysis was to evaluate the efficacy of the combined strategy in this setting. For this purpose, we performed a literature search of randomized controlled trials comparing PD-(L)1 inhibitors plus platinum-based chemotherapy versus chemotherapy alone in stage IV NSCLC patients. Seven clinical trials with 4562 patients were included. In the intention-to-treat wildtype population, PD-(L)1 inhibitor plus chemotherapy was significantly associated with improved progression-free survival (PFS) (Hazard ratio (HR) = 0.61, 95% confidence interval (CI): 0.57-0.65, p < 0.001) and overall survival (OS) (HR = 0.76, 95% CI: 0.67-0.86; p < 0.001) compared to chemotherapy. A significantly higher overall response rate (ORR) was also observed with the combined strategy (Odds ratio (OR) = 2.12, 95% CI: 1.70-2.63, p < 0.001). Furthermore, in all the analyzed subgroups, addition of PD-(L)1 inhibitors to chemotherapy significantly improved efficacy endpoints. Specifically, stratification according to PD-L1 expression revealed a benefit across all patients, regardless of their PFS status. In conclusion, PD-(L)1 blockade added to standard platinum-based chemotherapy significantly improved PFS, OS, and ORR in the up-front treatment of advanced NSCLC.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titlePD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysisen
dc.typeJournal Articlees
dc.authorsophosGarcía-González, Jorge;Ruiz-Bañobre, Juan;Afonso-Afonso, Francisco J.;Amenedo-Gancedo, Margarita;Areses-Manrique, María Del Carmen;Campos-Balea, Begoña;Casal-Rubio, Joaquín;Fernández-Núñez, Natalia;Fírvida Pérez, José Luis;Lázaro-Quintela, Martín;Pérez Parente, Diego;Crama, Leonardo;Ruiz-Gracia, Pedro;Santomé-Couto, Lucía;León-Mateos, Luis
dc.identifier.doi10.3390/jcm9072093
dc.identifier.pmid32635291
dc.identifier.sophos36407
dc.issue.number7es
dc.journal.titleJournal of Clinical Medicinees
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ferrol – Complexo Hospitalario Universitario de Ferrol::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Lugo, Cervo e Monforte de lemos - Complexo Hospitalario Universitario Lucus Augusti::Oncoloxía médicaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.page.initial2093es
dc.relation.publisherversionhttps://mdpi-res.com/d://attachment/jcm/jcm-09-02093/article://deploy/jcm-09-02093-v2.pdfes
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUFes
dc.subject.keywordCHUSes
dc.subject.keywordCHUOes
dc.subject.keywordCHUVIes
dc.subject.keywordHULAes
dc.subject.keywordIDISes
dc.typefidesArtículo de Revisiónes
dc.typesophosArtículo de Revisiónes
dc.volume.number9es


Ficheiros no ítem

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Atribución 4.0 Internacional
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAtribución 4.0 Internacional